Tirzepatide and Semaglutide are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Dual agonist meets the benchmark
The incretin class advances by adding receptors, and these two compounds sit on adjacent rungs of that ladder. Semaglutide is the single-receptor benchmark that made the whole field famous; Tirzepatide is the first molecule to prove that engaging a second incretin receptor beats engaging one. The core difference is one arm — the addition of GIP agonism on top of GLP-1 — and almost everything that separates the two flows from it. For the wider picture that folds in the triple agonist Retatrutide as well, our Semaglutide vs Tirzepatide vs Retatrutide comparison sets all three side by side. Here we narrow the field to the two FDA-approved frontrunners.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Class / peptide type | Dual agonist ("twincretin") | GLP-1 receptor agonist (mono) |
| Receptor targets | GIP + GLP-1 | GLP-1 (single) |
| Developer / brands | Eli Lilly · Mounjaro / Zepbound | Novo Nordisk · Ozempic / Wegovy |
| Structure / MW | 39-aa peptide, C20 fatty-acid tail · ~4,813 Da | 31-aa peptide, C18 fatty-diacid tail · ~4,114 Da |
| Approx. half-life | ~5 days | ~7 days (~165 h) |
| Headline trial result | ~22.5% weight reduction (SURMOUNT-1) | ~14.9% weight reduction (STEP-1) |
| Regulatory status | FDA-approved | FDA-approved |
Tirzepatide: adding the GIP arm
Tirzepatide (Eli Lilly, developer code LY3298176, marketed as Mounjaro and Zepbound) is a first-in-class dual agonist of the GIP and GLP-1 receptors — a single 39-amino-acid peptide engineered to activate both incretin systems at once, which is why the literature calls it a "twincretin". A C20 fatty-acid tail promotes reversible albumin binding, giving it a half-life of around five days and supporting a once-weekly research schedule.
The design idea is that GLP-1 and GIP act on overlapping but non-identical tissues — satiety circuits, pancreatic β-cells and adipose tissue — so co-activating both produces complementary effects a single receptor cannot match. That thesis held up in the data: in the Phase 3 SURMOUNT-1 obesity trial Tirzepatide reached approximately 22.5% mean body-weight reduction at its top dose, and in the head-to-head SURPASS-2 diabetes trial it outperformed once-weekly semaglutide on glycaemic control. It is the compound that turned "add another receptor" from a hypothesis into a strategy. Full detail sits on our Tirzepatide knowledgebase page, and research-grade material is on the buy Tirzepatide UK page.
Semaglutide: the single-agonist benchmark
Semaglutide (Novo Nordisk, marketed as Ozempic, Wegovy and Rybelsus) is a pure GLP-1 receptor agonist — one target, engaged with high selectivity. It is a 31-amino-acid analogue of native GLP-1, modified to resist DPP-4 cleavage and conjugated to a C18 fatty-diacid chain that drives albumin binding and stretches its half-life to roughly seven days, the longest of the pair. It, too, doses once weekly.
Where Semaglutide leads is not breadth of mechanism but depth of evidence. In the Phase 3 STEP-1 trial it produced a mean 14.9% body-weight reduction, and — uniquely in the class — the SELECT cardiovascular-outcomes trial showed it cut major adverse cardiovascular events by about 20% in adults with obesity and established cardiovascular disease but without diabetes. No other incretin compound has reached that hard-endpoint milestone. For research purposes it is the natural reference point: the single-receptor baseline against which dual agonism is judged. See the Semaglutide knowledgebase page for the full profile, or the buy Semaglutide UK page for research material.
What the differences mean in a research context
The contrast comes down to one variable: the GIP arm. Tirzepatide's dual mechanism lifted the ceiling on weight and glycaemic effect above the single-agonist baseline, and the SURPASS-2 head-to-head — the one trial designed to compare the two directly — put a controlled number on that gap in Tirzepatide's favour. For a researcher, the two compounds function almost as a clean pair: hold GLP-1 agonism constant, add or remove GIP, and watch what changes downstream. That is precisely why they are studied together rather than in isolation.
But the effect sizes deserve a caveat. The ~22.5% and ~14.9% headline figures come from different trials — SURMOUNT-1 and STEP-1 — with different populations, durations and protocols, so they describe a trend rather than a controlled ranking; SURPASS-2 is the exception that was built for a direct read. And magnitude of weight effect is not the only axis. Semaglutide carries the deepest and longest clinical dataset in the class and the only completed hard-endpoint cardiovascular-outcomes trial in a non-diabetic obesity population, so on evidence maturity it still leads. Half-life differs too: Semaglutide's ~7 days versus Tirzepatide's ~5, a distinction that matters for accumulation and steady-state behaviour in any research model.
The bottom line
Semaglutide set the benchmark with one receptor and owns the deepest evidence base; Tirzepatide raised the ceiling by adding GIP and won the one head-to-head trial that pitched them directly. Neither strictly supersedes the other — they are the mono and dual reference points of the incretin class, and the choice between them in a research setting depends on which variable you are probing. For research-grade material, see our dedicated pages to buy Tirzepatide UK and buy Semaglutide UK, each ≥99% purity with a COA.